- Onconova Therapeutics (ONTX) tumbles 13% premarket.
- The company has discontinued ONTRAC (Phase 3 IV rigosertib/gemcitabine in front-line metastatic pancreatic cancer) after the DSMB said the combo treatment wasn't likely to "demonstrate a statistically significant improvement in overall survival compared to gemcitabine alone."
- ONTX is "very disappointed." (PR)
Onconova discontinues rigosertib study, shares slide
Dec 18 2013, 08:17 ET